Tirofiban
Administration
- Type: Antiplatelet
- Dosage Forms: INJ
- Routes of Administration: IV
- Common Trade Names: Aggrastat
Adult Dosing
Acute coronary syndrome, Non ST-elevation
- 25 mcg/kg IV x1, then 0.15 mcg/kg/min IV for up to 18h
Pediatric Dosing
Safety/efficacy not established in pediatric patients
Special Populations
Pregnancy Rating
- Category B
- Benefits outweigh risks during pregnancy
- Risk of maternal hemorrhage during delivery
- Risk of fetal bleeding
Lactation risk
- Caution advised while breastfeeding
Renal Dosing
- Adult:
- CrCl <60: Decrease maintenance infusion rate 50%
- HD: Not defined
- Pediatric: Unavailable
Hepatic Dosing
- Adult: Not defined
- Pediatric: Unavailable
Contraindications
- Allergy to class/drug
- Thrombocytopenia with prior use
- Active bleeding
- Coagulation disorder w/in 30 days
- Major trauma or surgery w/in 30 days
Adverse Reactions
Serious
- Anaphylaxis
- Bleeding, severe
- Intracranial hemorrhage
- Intraocular hemorrhage
- Retroperitoneal bleeding
- Thrombocytopenia, severe
- Coronary artery dissection
Common
- Bleeding
- Pelvic pain
- Bradycardia
- Edema, Leg pain
- Dizziness, Diaphoresis
Pharmacology
- Half-life: 2 hour
- Metabolism: Minimal
- Excretion: Urine 65%, feces 25% (primarily unchanged)
Mechanism of Action
- Reversibly binds to platelet glycoprotein IIb/IIIa receptors, reducing platelet aggregation